Literature DB >> 29547460

Comparison of 6-year Follow-up Result of Hybrid Surgery and Anterior Cervical Discectomy and Fusion for the Treatment of Contiguous Two-segment Cervical Degenerative Disc Diseases.

Yang Xiong1, Lin Xu, Xing Yu, Yongdong Yang, Dingyan Zhao, Zhengguo Hu, Chuanhong Li, He Zhao, Lijun Duan, Bingbing Zhang, Sixue Chen, Tao Liu.   

Abstract

STUDY
DESIGN: A retrospective study.
OBJECTIVE: To compare the mid-term outcomes of hybrid surgery (HS) and anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-segment cervical degenerative disc diseases. SUMMARY OF BACKGROUND DATA: HS has become one of the most controversial subjects in spine communities, and the comparative studies of HS and ACDF in the mid- and long-term follow-up are rarely reported.
METHODS: From 2009 to 2012, 42 patients who underwent HS (n = 20) or ACDF (n = 22) surgery for symptomatic contiguous two-level cervical degenerative disc diseases were included. Clinical and radiological records, including Japanese Orthopedic Association (JOA), Neck Disability Index (NDI), Visual Analogue Scale (VAS), local cervical lordosis, and range of motion (ROM), were reviewed retrospectively. Complications were recorded and evaluated.
RESULTS: Mean follow-up was 77.25 and 79.68 months in HS group and ACDF group, respectively (P > 0.05). Both in HS group and ACDF group, significant improvement for the mean JOA, NDI, and VAS scores was found at 2-week postoperation and at the last follow-up (P < 0.05). However, there were no significant differences between the two groups (P > 0.05). At the last follow-up, the range of motion (ROM) of superior adjacent segments in ACDF group was significantly larger than HS group (P < 0.05), while the ROM of C2-C7 was significantly smaller (P < 0.05). In the HS group, two (10%) sagittal wedge deformities, one (5%) heterotopic ossification, and one (5%) anterior migration of the Byran disc prosthesis were found. No symptomatic adjacent segment degeneration occurred in two groups.
CONCLUSION: HS appears to be an acceptable option in the management of contiguous two-segment cervical degenerative disc diseases. It yielded similar mid-term clinical improvement to ACDF, and demonstrated better preservation of cervical ROM. The incidence of postoperative sagittal wedge deformity was low; however, it can significantly reduce the cervical lordosis. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Year:  2018        PMID: 29547460     DOI: 10.1097/BRS.0000000000002639

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  In which cases do surgeons specializing in total disc replacement perform fusion in patients with cervical spine symptoms?

Authors:  Richard D Guyer; Donna D Ohnmeiss; Scott L Blumenthal; Jack E Zigler
Journal:  Eur Spine J       Date:  2020-01-02       Impact factor: 3.134

2.  Exploration on sagittal alignment and clinical outcomes after consecutive three-level hybrid surgery and anterior cervical discectomy and fusion: a minimum of a 5-year follow-up.

Authors:  Shuai Xu; Yan Liang; Guanjie Yu; Zhenqi Zhu; Kaifeng Wang; Haiying Liu
Journal:  J Orthop Surg Res       Date:  2020-02-26       Impact factor: 2.359

3.  Anterior hybrid construction of multilevel cervical disc disease and spondylotic spinal stenosis: surgical results and factors affecting adjacent segment problems.

Authors:  Murat Yilmaz; Kemal Yucesoy; Resat S Erbayraktar; Rıfat S Altinag
Journal:  J Orthop Surg Res       Date:  2021-05-05       Impact factor: 2.359

4.  Kinematics of a cervical disc prosthesis implanted above or below one- and two-level fusions.

Authors:  Muturi G Muriuki; Robert M Havey; Jehad Zakaria; Kenneth R Blank; Suguna Pappu; Avinash G Patwardhan
Journal:  N Am Spine Soc J       Date:  2022-09-15

5.  A Comparison of 2 Anterior Hybrid Techniques for 3-Level Cervical Degenerative Disc Disease.

Authors:  Han Wang; Yang Meng; Hao Liu; Xiaofei Wang; Chen Ding
Journal:  Med Sci Monit       Date:  2020-11-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.